Immuno-Oncology Xchange Europe 2019

Immune Biomarkers

Titles and Bullets
8:00am – 8:30am


8:30am – 9:00am

Opening Address & Keynote: Immuno-Oncology: Back to Nature – A Historical Perspective (Geert Mudde, Chief Scientific Officer, Tyg Oncology)

9:05am – 10:05am

Developing predictive biomarkers for immune checkpoints
  • What are the recognized and perhaps less recognized predictive biomarkers for immune checkpoint inhibitors or other immuno therapies?
  • Are you using biomarker responses in your clinical trials with immuno therapies?
  • How are you undertaking to develop novel prognostic or predictive biomarkers?

Chief Medical Officer

After obtaining his Medical Doctor degree in Medical Microbiology at the University of Mainz (Germany) in 1992, Michael Lahn was a fellow at the Department of Hematology and Oncology at the University of Freiburg (Germany).  In 1996, he joined the Department of Immunology at National Jewish Research and Medical Center in Denver, Colorado, where he was Instructor.  During this time he investigated the role of  T cells in early immune responses.  In 2000, Michael joined Eli Lilly and Company, where he led drug development teams in early phase drug development for anti-inflammatory and oncology medicines.  He was responsible for the development of several novel oncology drugs, including the second generation ASO LY2181308 and the TGF-beta small molecule inhibitor galunisertib.  In 2014 Michael joined AstraZeneca’s osimertinib team and contributed to the registration of osimertinib in NSCLC.  In Fall of 2015, Michael was named Head of Clinical Development, Europe, at Incyte. He built the global cross-functional drug development team at Incyte’s European hub in Switzerland.  In 2019, he joined iOnctura as Chief Medical Officer in Geneva.  Michael has authored or co-authored over 100 publications.

Portrait picture of Michael Lahn
10:10am – 10:40am

1-2-1 Meetings / Networking Break

10:40am – 10:50am

Morning Refreshments

10:50am – 11:50am

Screening T cells by function: biomarker discovery with direct linkage between phenotype and gene expression 
  • What are your requirements for studying T cell interactions vs. primary tumour targets in order to investigate individual cell function and measure cytotoxicity in a single experiment?
  • How important is precise data on thousands of discrete single T-cell:target interactions for you?
  • How do you judge the need for a more reliable method for assessment of potency and viability?
  • What is your opinion on the importance of recovering individual T-cells of interest, post-assay, alive and why?

Director, Business Development – Europe
Berkeley Lights

Mio Muelthaler has earned his PhD in Molecular Biology at the University of Wuerzburg. He also earned a certificate „Business Science & Management“ in Munich. His career started in R&D at nanotype GmbH, a biotech start-up near Martinsried, where he contributed to the measurement of the smallest binding force ever measured between biomolecules. He also worked at Sigma-Aldrich as Sales Development Manager Life-Science and eCom manager Switzerland, Tecan as a lab-automation and robotics specialist and at Molecular Devices advising drug discovery and bioproduction development customers for e.g. HTP imaging. Today he is responsible for BD in EU at Berkeley Lights.

Portrait picture of Mio Muelthaler
11:55am – 12:25am

1-2-1 Meetings / Networking Break

12:30pm – 1:30pm

Evaluating biomarkers for treatment selection and monitoring
  • Biomarker – What are we talking about? Predictive, diagnostic, prognostic, ….?
  • Is there a general or preferred path how to implement biomarker development in the
  • overall drug development process?
  • What are the key lessons to be learned from approved immuno-oncology therapeutics?

Chief Eecutive Officer

Randolf Kerschbaumer holds a degree in biotechnology and a PhD from the University of

Natural Resources and Life Sciences, Vienna, Austria. He has more than twenty years of

experience in research and development of biotherapeutics in big pharma organizations and small biotech companies. During his career he held various senior positions, including Head

of Oncology Research at Shire and Head of Antibody Technology at Baxter. He acquired

detailed knowledge of the entire drug development process, from early drug screening to clinical development, in areas of oncology, inflammation and hematologic disorders. Randolf is founder and CEO of OncoOne, an early stage biotech start-up company based in Klosterneuburg near Vienna, Austria.

Portrait picture of Randolf Kerschbaumer
1:30pm – 2:30pm

Networking Lunch

2:30pm – 3:00pm

Poster Session: T Cell functional analytics on the Lightning™ platform – Berkeley Lights

3:00pm – 3:30pm

1-2-1 Meetings / Networking Break

3:30pm – 3:40pm

Afternoon Refreshments

3:40pm – 4:10pm

1-2-1 Meetings / Networking Break

5:15pm – 5:45pm

Closing Keynote & Address: Unlocking Potent Pharmacology (Jonny Finlay, CEO, UltraHuman)


Canape/Drinks Reception


Immuno-Oncology Xchange | Europe 2019